Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARITIME-HF
NL-OMON61064Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Oct 2025
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF), heart failure with mid-range ejection fraction (HFmrEF) and obesity comparing Maridebart cafraglutide + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Time to first occurrence of composite cardiovascular death or heart failure event. Started Oct 2025; status: recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)obesity
Beyond the preview
Go deeper on NL-OMON61064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61064.